The Oncologist
The official journal of the Society for Translational Oncology

Supplemental Table for:
Clinical application of targeted deep sequencing in solid-cancer patients: Utility of targeted deep sequencing for biomarker-selected clinical trial
Seung Tae Kim et al.

Table S1. Statistics of targeted deep sequencing for 418 patients

Type	ID	GC %	Q30	Coverage	Panel version	Read count	Sequencing depth	On-target rate
11	15_00050_DT_CS	46	92.8	1,618	CS_v1	15,103,446	1,618	64.01%
11	15_00051_DT_CS	46	92.4	1,573	CS_v1	15,779,422	1,573	61.98%
11	15_00052_DT_CS	46	92.5	1,611	CS_v1	16,675,454	1,611	63.14%
11	15_00053_DT_CS	46	92.7	1,414	CS_v1	14,954,040	1,414	61.59%
11	15_00056_DP_CS	51	91.2	1,047	CS_v1	15,481,914	1,047	57.10%
11	15_00142_DP_CS	48	91.4	1,291	CS_v1	13,647,088	1,291	60.10%
11	15_00161_DP_CS	48	90.4	1,476	CS_v1	14,469,516	1,476	62.82%
11	15_00163_DP_CS	49	89.9	1,144	CS_v1	12,391,838	1,144	59.19%
11	15_00164_DP_CS	49	90.6	1,438	CS_v1	13,416,504	1,438	63.51%
11	15_00171_DT_CS	45	90.3	1,111	CS_v2	44,023,864	1,111	56.83%
11	15_00192_DP_CS	49	90.5	1,248	CS_v1	15,018,642	1,248	60.78%
11	15_00193_DP_CS	48	90.8	1,382	CS_v1	14,863,180	1,382	63.22%
11	15_00195_DP_CS	50	90	1,477	CS_v1	14,736,904	1,477	63.50%
11	15_00196_DP_CS	49	90.1	1,646	CS_v1	15,368,182	1,646	65.08%
11	15_00197_DP_CS	48	87.6	1,511	CS_v1	14,696,610	1,511	63.90%
11	15_00198_DP_CS	50	90.6	789	CS_v1	14,119,364	789	52.04%
11	15_00199_DP_CS	47	90.5	1,349	CS_v1	14,896,952	1,349	62.24%
11	15_00200_DP_CS	47	90.4	1,508	CS_v1	15,345,030	1,508	62.24%
11	15_00201_DP_CS	49	90.2	1,571	CS_v1	15,589,650	1,571	62.21%
11	15_00249_DT_CS	46	90.4	1,128	CS_v1	12,196,870	1,128	61.42%
11	15_00251_DT_CS	46	90.1	1,289	CS_v1	13,453,330	1,289	63.14%
11	15_00266_DP_CS	48	87.8	851	CS_v2	47,298,516	851	54.59%
11	15_00267_DP_CS	49	88.7	583	CS_v2	50,211,830	583	46.24%
11	15_00268_DP_CS	49	89.1	732	CS_v2	48,784,970	732	51.21%
11	15_00271_DP_CS	52	86.9	609	CS_v2	47,244,878	609	48.40%
11	15_00383_DT_CS	45	92.2	894	CS_v2	36,617,952	894	56.12%
11	15_00386_DP_CS	48	92.2	966	CS_v2	39,386,874	966	56.96%
11	15_00402_DP_CS	49	89.9	1,199	CS_v1	12,561,972	1,199	63.99%
11	15_00403_DP_CS	49	91.8	902	CS_v2	37,187,150	902	57.03%
11	15_00410_DP_CS	48	90.7	874	CS_v2	36,210,458	874	58.12%
11	15_00417_DT_CS	45	92.3	944	CS_v2	39,315,712	944	54.98%
11	15_00418_DT_CS	45	92.2	892	CS_v2	36,943,786	892	55.89%
11	15_00424_DP_CS	48	90.5	964	CS_v2	44,528,378	964	53.89%
11	15_00427_DP_CS	49	88.1	849	CS_v2	42,520,116	849	57.13%
11	15_00428_DP_CS	47	89.8	975	CS_v2	38,781,744	975	57.43%
11	15_00433_DP_CS	49	90.9	1,023	CS_v2	42,008,560	1,023	55.60%
11	15_00434_DP_CS	51	88.9	911	CS_v2	39,951,156	911	56.64%
11	15_00435_DP_CS	51	89.7	923	CS_v2	38,783,360	923	55.67%
11	15_00439_DP_CS	52	90.4	652	CS_v2	44,926,004	652	51.90%
11	CS11_14_01300	46	90.2	772	CS_v1	9,353,756	772	56.32%
11	CS11_14_01307	47	89.7	876	CS_v1	9,738,702	876	57.86%
11	CS11_14_01311	46	89.3	1,002	CS_v1	9,952,412	1,002	62.78%
11	CS11_14_01313	46	88.6	577	CS_v1	5,528,874	577	63.45%
11	CS11_14_01316	46	88.7	966	CS_v1	9,820,634	966	60.63%
11	CS11_14_01318	47	90	624	CS_v1	7,963,106	624	66.33%
11	CS11_14_01319	46	88.7	992	CS_v1	9,171,596	992	65.28%
11	CS11_14_01321	45	89.8	993	CS_v1	9,525,364	993	64.43%

The Oncologist
The official journal of the Society for Translational Oncology

Supplemental Table for:
Clinical application of targeted deep sequencing in solid-cancer patients: Utility of targeted deep sequencing for biomarker-selected clinical trial
Seung Tae Kim et al.

11	CS11_14_01329	47	88.8	643	CS_v1	11,559,130	643	52.00%
11	CS11_14_01343	46	89.2	960	CS_v1	11,672,844	960	51.52%
11	CS11_14_01359	47	89.9	645	CS_v1	11,394,394	645	50.02%
11	CS11_14_01361	47	89.7	784	CS_v1	11,430,708	784	50.16%
11	CS11_14_01365	47	90.3	494	CS_v1	9,426,320	494	52.56%
11	CS11_14_02245	45	94	634	CS_v1	5,444,890	634	64.10%
11	CS11_14_02251	45	93.7	670	CS_v1	5,368,764	670	68.45%
11	CS11_14_02308	50	89.3	897	CS_v1	10,264,694	897	61.36%
11	CS11_14_02309	48	89.3	1,045	CS_v1	10,411,042	1,045	58.07%
11	CS11_14_02310	50	90.1	1,242	CS_v1	11,068,824	1,242	63.96%
11	CS11_14_02322	46	93.1	1,066	CS_v1	9,848,722	1,066	68.21%
11	CS11_14_02324	46	93.7	1,302	CS_v1	12,148,144	1,302	63.86%
11	CS11_14_02325	46	93.5	1,005	CS_v1	11,902,898	1,005	58.78%
11	CS11_14_02329	47	92.8	1,265	CS_v1	11,937,274	1,265	63.75%
11	CS11_14_02332	49	92.1	395	CS_v1	13,180,912	395	62.50%
11	CS11_14_02334	50	92.2	510	CS_v1	13,266,084	510	67.18%
11	CS11_14_02345	46	89.9	956	CS_v1	10,166,528	956	61.89%
11	CS11_14_02490	49	89.2	1,082	CS_v1	12,847,596	1,082	60.40%
11	CS11_14_02559	50	89.5	1,237	CS_v1	10,588,162	1,237	71.14%
11	CS11_14_02560	47	87.9	1,314	CS_v1	10,737,462	1,314	72.99%
11	CS11_14_02565	46	90.2	1,298	CS_v1	12,598,218	1,298	65.24%
11	CS11_14_02600	49	90.2	1,186	CS_v1	10,692,932	1,186	70.98%
11	CS11_14_02602	50	90.4	1,109	CS_v1	10,764,230	1,109	67.35%
11	CS11_14_02640	49	89.7	1,132	CS_v1	11,290,810	1,132	67.89%
11	CS11_14_02677	47	88.8	1,124	CS_v1	11,315,348	1,124	63.42%
11	CS11_14_02678	46	91	1,027	CS_v1	10,861,148	1,027	64.77%
11	CS11_14_02679	45	90	948	CS_v1	11,663,542	948	65.09%
11	CS11_14_02686	49	91.1	1,233	CS_v2	49,766,254	1,233	15.69%
11	CS11_14_02705	50	90	203	CS_v2	45,987,500	203	10.13%
11	CS11_14_02708	47	90.4	1,072	CS_v2	47,475,412	1,072	15.23%
11	CS11_14_02710	50	90	1,059	CS_v2	44,493,778	1,059	15.84%
11	CS11_14_02717	45	90.9	1,092	CS_v2	43,323,002	1,092	15.98%
11	CS11_14_02718	45	91.6	1,228	CS_v2	47,522,456	1,228	15.69%
11	CS11_14_02928	50	90.2	101	CS_v2	35,523,098	101	10.24%
11	CS11_14_02929	49	91.1	1,093	CS_v2	44,081,180	1,093	16.03%
11	CS11_14_02996	47	90.9	1,221	CS_v2	48,033,588	1,221	15.24%
11	CS11_14_03001	44	91	1,109	CS_v2	44,592,594	1,109	14.71%
11	CS11_14_03244	49	88.7	1,159	CS_v2	47,319,146	1,159	15.17%
11	CS11_14_03359	45	91.4	1,023	CS_v2	46,462,530	1,023	15.44%
11	D_15_00765_DP_CS	50	90.8	1,006	CS_v2	44,646,148	1,006	55.68%
11	D_15_00766_DP_CS	49	91.2	930	CS_v2	39,717,318	930	57.53%
11	D_15_00767_DP_CS	49	90.5	990	CS_v2	42,770,776	990	56.54%
11	D_15_00799_DP_CS	51	89.1	457	CS_v2	39,616,560	457	46.80%
11	D_15_00800_DP_CS	47	91.9	1,028	CS_v2	49,379,850	1,028	54.22%
11	D_15_00813_DP_CS	47	90.6	963	CS_v2	40,335,838	963	53.50%
11	D_15_00814_DP_CS	48	90.4	971	CS_v2	41,007,380	971	53.63%
11	D_15_00852_DP_CS	45	91	705	CS_v2	38,963,528	705	51.57%
11	D_15_00866_DP_CS	49	89	978	CS_v2	40,828,776	978	59.55%
11	D_15_00867_DP_CS	50	88.5	772	CS_v2	39,898,772	772	54.92%
11	D_15_00868_DP_CS	49	89.8	822	CS_v2	38,919,990	822	57.89%
11	D_15_01008_DP_CS	48	90.2	619	CS_v2	38,460,280	619	54.59%

The Oncologist
The official journal of the Society for Translational Oncology

Supplemental Table for:
Clinical application of targeted deep sequencing in solid-cancer patients: Utility of targeted deep sequencing for biomarker-selected clinical trial
Seung Tae Kim et al.

11	D_15_01013_DP_CS	50	92	251	CS_v2	33,214,060	251	42.58%
11	D_15_01019_DT_CS	46	91.4	794	CS_v2	41,914,908	794	56.19%
11	D_15_01020_DT_CS	46	92.3	774	CS_v2	42,626,176	774	54.11%
11	D_15_01022_DT_CS	45	91.2	929	CS_v2	38,456,364	929	58.12%
11	D_15_01086_DP_CS	51	88.9	921	CS_v2	39,522,836	921	56.07%
11	D_15_01087_DP_CS	46	92	794	CS_v2	39,987,272	794	56.38%
11	D_15_01088_DP_CS	48	90.3	849	CS_v2	37,925,896	849	57.75%
11	D_15_01092_DT_CS	45	90.3	840	CS_v2	38,736,514	840	56.55%
11	D_15_01159_DP_CS	50	90.5	818	CS_v2	41,388,068	818	55.18%
11	D_15_01166_DP_CS	50	90.6	874	CS_v2	38,529,212	874	58.34%
11	D_15_01216_DT_CS	45	90.3	961	CS_v2	40,840,278	961	56.11%
11	D_15_01217_DT_CS	46	90.3	970	CS_v2	42,184,490	970	55.79%
11	D_15_01218_DT_CS	45	89.8	978	CS_v2	41,436,460	978	55.94%
11	D_15_01232_DT_CS	45	90.6	970	CS_v2	41,976,294	970	54.73%
11	D_15_01273_DP_CS	48	89.3	784	CS_v2	38,624,052	784	52.32%
11	D_15_01431_DP_CS	47	88.8	1,156	CS_v2	56,382,814	1,156	54.63%
11	D_15_01432_DP_CS	49	88.2	645	CS_v2	41,465,768	645	50.76%
11	D_15_01437_DT_CS	45	91.4	749	CS_v2	32,663,920	749	53.62%
11	D_15_01440_DT_CS	45	92.3	879	CS_v2	38,262,100	879	53.85%
11	D_15_01448_DP_CS	50	88.5	990	CS_v2	41,078,778	990	59.70%
11	D_15_01451_DP_CS	48	90.5	866	CS_v2	39,845,010	866	55.31%
11	D_15_01460_DT_CS	45	89.4	865	CS_v2	47,199,806	865	52.87%
11	D_15_01464_DP_CS	53	90	488	CS_v2	35,092,748	488	51.01%
11	D_15_01753_DP_CS	47	92.4	802	CS_v2	38,832,582	802	54.32%
11	D_15_01755_DP_CS	51	87.8	836	CS_v2	34,714,256	836	56.13%
11	D_15_01758_DP_CS	50	87.7	1,087	CS_v2	43,409,600	1,087	58.56%
11	D_15_01789_DP_CS	49	90.2	1,007	CS_v2	40,865,646	1,007	58.10%
11	D_15_01790_DP_CS	48	90.2	938	CS_v2	38,165,890	938	56.50%
11	D_15_01796_DP_CS	51	89.2	795	CS_v2	38,433,672	795	55.49%
12	15_00058_DP_CS	50	91.8	1,565	CS_v1	15,630,264	1,565	63.71%
12	15_00059_DP_CS	48	91.5	1,502	CS_v1	15,815,674	1,502	61.95%
12	15_00064_DP_CS	49	91.2	1,490	CS_v1	15,415,552	1,490	62.59%
12	15_00066_DP_CS	50	90.9	1,402	CS_v1	14,611,736	1,402	63.23%
12	15_00067_DP_CS	51	90.8	1,746	CS_v1	16,881,594	1,746	63.72%
12	15_00165_DP_CS	50	90.5	1,219	CS_v1	13,312,356	1,219	60.04%
12	15_00166_DP_CS	50	90.8	1,447	CS_v1	14,908,186	1,447	61.33%
12	15_00202_DT_CS	46	90.6	1,528	CS_v1	14,600,702	1,528	63.52%
12	15_00222_DP_CS	50	89.3	1,007	CS_v1	12,050,202	1,007	63.32%
12	15_00224_DP_CS	49	90.5	900	CS_v1	14,046,244	900	57.52%
12	15_00225_DP_CS	49	89	1,486	CS_v1	14,930,638	1,486	64.27%
12	15_00228_DP_CS	50	88.7	1,253	CS_v1	13,088,304	1,253	67.58%
12	15_00250_DT_CS	46	89.8	1,170	CS_v1	12,767,800	1,170	60.97%
12	15_00252_DT_CS	46	90.6	1,185	CS_v1	12,463,378	1,185	63.05%
12	15_00262_DT_CS	45	90	1,139	CS_v2	53,604,586	1,380	58.14%
12	15_00265_DT_CS	45	89.8	1,380	CS_v2	46,092,042	1,139	56.84%
12	15_00280_DP_CS	47	92.3	932	CS_v2	38,634,456	932	58.68%
12	15_00281_DP_CS	49	92.1	698	CS_v2	37,113,168	698	55.01%
12	15_00405_DP_CS	50	92	475	CS_v2	39,684,890	475	48.70%
12	15_00408_DP_CS	49	90.5	938	CS_v2	39,005,958	938	57.70%
12	15_00409_DP_CS	51	90.3	688	CS_v2	38,658,906	688	52.63%
12	15_00411_DP_CS	48	90.7	891	CS_v2	38,047,568	891	56.92%

The Oncologist
The official journal of the Society for Translational Oncology

Supplemental Table for:
Clinical application of targeted deep sequencing in solid-cancer patients: Utility of targeted deep sequencing for biomarker-selected clinical trial
Seung Tae Kim et al.

12	15_00415_DT_CS	46	91.3	935	CS_v2	39,988,428	935	55.70%
12	15_00420_DT_CS	45	91.3	831	CS_v2	37,448,568	831	54.53%
12	15_00431_DP_CS	49	91.3	876	CS_v2	43,794,182	876	56.84%
12	15_00432_DP_CS	48	90.9	1,081	CS_v2	43,367,344	1,081	56.69%
12	15_00437_DT_CS	45	91.4	1,013	CS_v2	40,185,004	1,013	58.10%
12	15_00440_DP_CS	49	90.8	1,031	CS_v2	40,349,462	1,031	57.60%
12	CS11_14_01303	46	89.6	752	CS_v1	9,711,072	752	55.18%
12	CS11_14_01312	46	88.5	1,125	CS_v1	11,616,886	1,125	61.74%
12	CS11_14_01323	45	90.1	978	CS_v1	9,183,150	978	62.79%
12	CS11_14_01334	48	89.4	673	CS_v1	10,558,318	673	52.12%
12	CS11_14_01346	47	89.8	979	CS_v1	11,353,158	979	52.13%
12	CS11_14_01348	46	88.1	815	CS_v1	10,154,464	815	51.06%
12	CS11_14_01355	47	88.1	890	CS_v1	11,134,392	890	50.97%
12	CS11_14_01474	44	87.5	834	CS_v1	8,036,924	834	63.49%
12	CS11_14_01476	45	88.3	847	CS_v1	8,474,728	847	60.87%
12	CS11_14_01480	44	93.5	1,034	CS_v1	10,385,870	1,034	62.48%
12	CS11_14_01481	44	93.9	861	CS_v1	8,081,222	861	63.92%
12	CS11_14_01485	44	94.5	943	CS_v1	8,538,928	943	64.57%
12	CS11_14_01486	45	93.9	828	CS_v1	7,479,752	828	64.31%
12	CS11_14_01492	45	89.7	1,156	CS_v1	11,679,886	1,156	64.02%
12	CS11_14_02246	45	93.8	652	CS_v1	5,547,068	652	65.73%
12	CS11_14_02250	45	93.6	666	CS_v1	5,449,206	666	67.77%
12	CS11_14_02252	45	94.2	671	CS_v1	5,532,922	671	66.51%
12	CS11_14_02253	46	93.1	598	CS_v1	4,927,134	598	66.80%
12	CS11_14_02314	51	89.7	838	CS_v1	9,725,956	838	58.32%
12	CS11_14_02320	46	92.9	1,009	CS_v1	9,846,662	1,009	61.74%
12	CS11_14_02326	45	92.7	1,173	CS_v1	12,112,496	1,173	58.41%
12	CS11_14_02328	45	93.7	1,164	CS_v1	10,562,852	1,164	63.37%
12	CS11_14_02330_re	44	93.2	502	CS_v1	25,091,072	502	11.92%
12	CS11_14_02331	47	93.7	1,070	CS_v1	11,452,340	1,070	55.26%
12	CS11_14_02343	46	90.2	1,035	CS_v1	11,210,268	1,035	62.16%
12	CS11_14_02488	50	89.1	1,276	CS_v1	13,508,302	1,276	63.37%
12	CS11_14_02491	49	89.6	940	CS_v1	11,803,328	940	61.03%
12	CS11_14_02492	52	87.9	1,107	CS_v1	11,834,646	1,107	60.83%
12	CS11_14_02493	52	88.7	972	CS_v1	12,429,886	972	59.85%
12	CS11_14_02495	49	89.8	1,052	CS_v1	13,927,302	1,052	58.42%
12	CS11_14_02497	51	89.3	995	CS_v1	11,848,704	995	59.09%
12	CS11_14_02498	50	91.3	466	CS_v1	11,540,716	466	66.53%
12	CS11_14_02563	51	88.9	1,310	CS_v1	12,181,130	1,310	68.65%
12	CS11_14_02595	46	90.1	1,339	CS_v1	11,482,546	1,339	69.64%
12	CS11_14_02598	50	89.6	1,136	CS_v1	9,747,892	1,136	70.78%
12	CS11_14_02674	47	91.1	1,216	CS_v2	49,517,166	1,216	15.86%
12	CS11_14_02683	46	88.9	1,317	CS_v1	12,311,252	1,317	69.80%
12	CS11_14_02701	46	91.1	1,299	CS_v2	50,141,878	1,299	16.21%
12	CS11_14_02702	47	89.9	948	CS_v1	10,012,262	948	63.86%
12	CS11_14_02709	48	90.6	942	CS_v2	45,513,428	942	15.03%
12	CS11_14_02940	46	91.2	1,086	CS_v2	45,433,790	1,086	15.93%
12	CS11_14_02943	46	90.4	989	CS_v2	42,407,188	989	15.22%
12	CS11_14_02944	46	91.7	1,137	CS_v2	44,004,438	1,137	16.30%
12	CS11_14_02948	45	92	1,232	CS_v2	46,298,034	1,232	16.55%
12	CS11_14_02950	46	92.3	1,138	CS_v2	46,994,608	1,138	15.69%

The Oncologist
The official journal of the Society for Translational Oncology

Supplemental Table for:
Clinical application of targeted deep sequencing in solid-cancer patients: Utility of targeted deep sequencing for biomarker-selected clinical trial
Seung Tae Kim et al.

12	CS11_14_02995	49	91.2	384	CS_v2	43,983,236	384	12.37%
12	CS11_14_03005	49	90.6	1,546	CS_v2	58,762,508	1,546	17.37%
12	CS11_14_03085	45	90.5	993	CS_v2	41,110,736	993	15.05%
12	CS11_14_03158	45	91.8	1,176	CS_v2	49,691,846	1,176	15.81%
12	CS11_14_03232	47	90.8	1,304	CS_v2	50,575,494	1,304	15.10%
12	CS11_14_03233	48	90.7	1,193	CS_v2	46,607,578	1,193	15.85%
12	CS11_14_03235	45	89.7	1,315	CS_v2	56,321,240	1,315	15.43%
12	CS11_14_03241	49	89.2	1,112	CS_v2	47,367,572	1,112	15.38%
12	CS11_14_03242	49	88.7	1,136	CS_v2	46,922,602	1,136	15.38%
12	CS11_14_03276	45	89.4	1,086	CS_v2	45,911,028	1,086	15.18%
12	CS11_14_03278	50	91	729	CS_v2	41,269,408	729	14.16%
12	CS11_14_03367	50	88.5	894	CS_v2	51,533,294	894	14.58%
12	CS11_14_03369	47	89.8	1,233	CS_v2	45,584,196	1,233	15.90%
12	CS11_14_03477	45	88.9	1,256	CS_v2	47,965,526	1,256	16.33%
12	D_15_00797_DT_CS	45	91.9	978	CS_v2	40,665,164	978	54.42%
12	D_15_00798_DT_CS	45	91.4	945	CS_v2	38,945,782	945	55.18%
12	D_15_00805_DP_CS	47	90.2	936	CS_v2	40,346,900	936	55.32%
12	D_15_00812_DP_CS	50	89.3	880	CS_v2	38,118,366	880	55.65%
12	D_15_00817_DP_CS	52	89.3	683	CS_v2	40,083,162	683	49.15%
12	D_15_00967_DT_CS	45	92.2	841	CS_v2	36,201,790	841	54.67%
12	D_15_00972_DT_CS	45	92.9	806	CS_v2	34,829,270	806	53.84%
12	D_15_00976_DT_CS	45	93.2	801	CS_v2	33,467,982	801	55.58%
12	D_15_00991_DT_CS	45	92.9	869	CS_v2	37,093,742	869	54.99%
12	D_15_00995_DT_CS	44	92.6	817	CS_v2	34,858,838	817	54.15%
12	D_15_00996_DT_CS	47	91.8	750	CS_v2	40,322,562	750	59.28%
12	D_15_00998_DT_CS	45	92.3	843	CS_v2	34,921,672	843	55.72%
12	D_15_01003_DT_CS	45	91.4	978	CS_v2	39,068,476	978	57.09%
12	D_15_01004_DT_CS	46	89	802	CS_v2	40,558,872	802	53.50%
12	D_15_01014_DP_CS	50	89.8	383	CS_v2	44,553,486	383	47.62%
12	D_15_01023_DT_CS	46	90.6	853	CS_v2	39,304,408	853	54.95%
12	D_15_01160_DP_CS	49	90.8	939	CS_v2	39,757,448	939	57.68%
12	D_15_01162_DP_CS	50	90.4	938	CS_v2	42,175,174	938	55.81%
12	D_15_01169_DP_CS	47	91	926	CS_v2	40,641,240	926	54.83%
12	D_15_01170_DP_CS	47	88.9	1,032	CS_v2	47,583,198	1,032	54.97%
12	D_15_01171_DP_CS	49	90.9	924	CS_v2	39,150,260	924	55.92%
12	D_15_01221_DP_CS	48	90.2	1,090	CS_v2	46,415,022	1,090	58.30%
12	D_15_01222_DP_CS	49	89	1,113	CS_v2	46,197,646	1,113	57.69%
12	D_15_01224_DP_CS	51	89.8	615	CS_v2	39,479,928	615	55.47%
12	D_15_01225_DP_CS	50	89.4	253	CS_v2	39,676,900	253	45.70%
12	D_15_01227_DP_CS	46	91.4	1,098	CS_v2	43,941,434	1,098	58.53%
12	D_15_01233_DT_CS	46	89.8	951	CS_v2	39,049,634	951	56.23%
12	D_15_01236_DT_CS	46	90.1	1,020	CS_v2	41,763,322	1,020	59.69%
12	D_15_01419_DP_CS	48	88.4	874	CS_v2	43,426,078	874	52.30%
12	D_15_01421_DP_CS	50	87.7	643	CS_v2	37,194,032	643	49.77%
12	D_15_01427_DP_CS	48	88.5	830	CS_v2	42,720,190	830	54.30%
12	D_15_01442_DP_CS	51	89.9	832	CS_v2	39,396,580	832	54.87%
12	D_15_01752_DP_CS	49	90.7	878	CS_v2	35,908,110	878	56.63%
12	D_15_01759_DP_CS	49	88.4	989	CS_v2	42,000,296	989	57.14%
12	D_15_01768_DT_CS	45	90.9	979	CS_v2	44,107,242	979	54.51%
13	15_00034_DT_CS	46	92.2	1,572	CS_v1	15,164,072	1,572	65.34%
13	15_00042_DP_CS	47	91	1,524	CS_v1	14,867,024	1,524	64.51%

The Oncologist
The official journal of the Society for Translational Oncology

Supplemental Table for:
Clinical application of targeted deep sequencing in solid-cancer patients: Utility of targeted deep sequencing for biomarker-selected clinical trial
Seung Tae Kim et al.

13	15_00061_DP_CS	48	90.8	1,148	CS_v2	46,165,738	1,148	57.75%
13	15_00062_DP_CS	51	89.7	174	CS_v1	12,703,602	174	30.73%
13	15_00160_DP_CS	51	90.1	1,377	CS_v1	16,730,018	1,377	58.74%
13	15_00168_DT_CS	46	91.2	1,475	CS_v1	14,735,188	1,475	63.28%
13	15_00221_DP_CS	50	89.2	1,406	CS_v1	13,357,184	1,406	66.29%
13	15_00223_DP_CS	51	88.4	939	CS_v1	12,688,580	939	59.84%
13	15_00227_DP_CS	50	89	1,353	CS_v1	14,303,234	1,353	61.70%
13	15_00254_DT_CS	49	89.3	1,407	CS_v2	42,703,602	1408.0	60.09%
13	15_00283_DP_CS	48	91.9	815	CS_v2	40,965,520	815	54.07%
13	15_00284_DP_CS	50	91.3	772	CS_v2	36,410,054	772	54.50%
13	15_00404_DP_CS	48	92.4	808	CS_v2	35,844,762	808	56.33%
13	15_00406_DP_CS	50	90.3	764	CS_v2	38,281,448	764	54.73%
13	15_00407_DP_CS	49	90.8	790	CS_v2	36,274,332	790	55.94%
13	15_00429_DP_CS	50	91	863	CS_v2	40,269,074	863	57.00%
13	CS11_14_01335	47	89.2	622	CS_v1	9,441,582	622	53.36%
13	CS11_14_01338	47	90.3	660	CS_v1	10,797,128	660	51.28%
13	CS11_14_01366	48	90.7	554	CS_v1	11,267,184	554	50.93%
13	CS11_14_02241	49	92.3	616	CS_v1	6,033,572	616	65.42%
13	CS11_14_02242	49	93.3	608	CS_v1	5,504,872	608	66.54%
13	CS11_14_02312	50	88.8	954	CS_v1	11,399,798	954	59.15%
13	CS11_14_02313	48	90	1,330	CS_v1	12,072,580	1,330	65.12%
13	CS11_14_02335	49	93.1	1,063	CS_v1	11,121,658	1,063	59.97%
13	CS11_14_02336	49	91	1,332	CS_v1	13,504,252	1,332	60.09%
13	CS11_14_02337	48	91.4	1,360	CS_v1	15,220,656	1,360	60.51%
13	CS11_14_02494	50	88.5	1,223	CS_v1	11,921,370	1,223	64.79%
13	CS11_14_02496	51	89.5	1,280	CS_v1	13,316,306	1,280	62.59%
13	CS11_14_02596	50	89.2	942	CS_v1	11,466,030	942	64.70%
13	CS11_14_02597	49	89.3	1,171	CS_v1	10,192,260	1,171	69.71%
13	CS11_14_02599	49	89.9	1,468	CS_v1	13,316,330	1,468	70.23%
13	CS11_14_02623	51	88.9	1,188	CS_v1	10,798,444	1,188	67.91%
13	CS11_14_02673	50	90.3	1,189	CS_v2	49,879,362	1,189	15.51%
13	CS11_14_02675	49	91.5	998	CS_v2	41,642,408	998	17.03%
13	CS11_14_02704	51	89.9	1,052	CS_v2	50,438,034	1,052	15.47%
13	CS11_14_02707	53	87.8	498	CS_v1	13,448,798	498	48.27%
13	CS11_14_02719	45	92	1,147	CS_v2	43,824,900	1,147	15.49%
13	CS11_14_03234	45	91.7	1,144	CS_v2	45,913,352	1,144	15.73%
13	CS11_14_03366	49	89.2	1,109	CS_v2	42,522,580	1,109	15.88%
13	CS11_14_03371	47	89.3	1,302	CS_v2	50,492,128	1,302	15.63%
13	D_15_00855_DP_CS	50	89.6	702	CS_v2	41,200,596	702	54.01%
13	D_15_01005_DP_CS	50	89.4	939	CS_v2	44,621,032	939	56.96%
13	D_15_01009_DP_CS	49	89.4	741	CS_v2	42,302,054	741	56.37%
13	D_15_01015_DP_CS	48	91.5	893	CS_v2	42,038,100	893	53.95%
13	D_15_01093_DT_CS	45	90.5	992	CS_v2	40,558,800	992	58.70%
13	D_15_01165_DP_CS	50	90.8	450	CS_v2	39,928,686	450	52.20%
13	D_15_01172_DP_CS	51	89.6	514	CS_v2	39,607,408	514	50.23%
13	D_15_01173_DP_CS	49	89.2	912	CS_v2	40,175,810	912	55.81%
13	D_15_01175_DP_CS	52	87.5	795	CS_v2	40,918,584	795	57.63%
13	D_15_01235_DP_CS	53	88.2	761	CS_v2	39,941,154	761	54.74%
13	D_15_01423_DP_CS	50	88.2	424	CS_v2	39,378,080	424	45.98%
13	D_15_01433_DP_CS	47	88	833	CS_v2	41,820,346	833	55.41%
13	D_15_01443_DP_CS	49	88	1,059	CS_v2	48,572,820	1,059	54.06%

The Oncologist
The official journal of the Society for Translational Oncology

Supplemental Table for:
Clinical application of targeted deep sequencing in solid-cancer patients: Utility of targeted deep sequencing for biomarker-selected clinical trial
Seung Tae Kim et al.

13	D_15_01447_DP_CS	48	91	923	CS_v2	40,102,812	923	54.09%
13	D_15_01449_DP_CS	52	87.1	1,109	CS_v2	50,245,184	1,109	57.81%
13	D_15_01760_DP_CS	51	87.4	768	CS_v2	39,014,144	768	53.96%
13	D_15_01761_DP_CS	50	90.6	662	CS_v2	41,791,596	662	52.59%
13	D_15_01769_DT_CS	45	91.1	1,030	CS_v2	43,985,198	1,030	57.95%
13	D_15_01788_DP_CS	48	90.3	1,027	CS_v2	40,287,190	1,027	59.69%
13	D_15_01791_DP_CS	51	88.8	800	CS_v2	44,320,936	800	52.27%
13	D_15_01792_DP_CS	51	89.4	977	CS_v2	41,603,686	977	56.66%
13	D_15_01798_DT_CS	45	91.3	882	CS_v2	39,560,160	882	50.87%
16	15_00043_DP_CS	49	91.5	1,764	CS_v1	17,985,116	1,764	63.54%
16	15_00162_DP_CS	50	89.2	1,472	CS_v1	13,962,930	1,472	63.29%
16	15_00274_DP_CS	48	90.1	1,034	CS_v2	44,804,336	1,034	58.47%
16	15_00275_DP_CS	48	89.1	920	CS_v2	46,237,072	920	55.92%
16	15_00276_DP_CS	48	89.1	1,093	CS_v2	50,681,786	1,093	56.00%
16	15_00277_DP_CS	48	89.2	1,057	CS_v2	50,636,356	1,057	54.53%
16	15_00278_DP_CS	49	88.8	794	CS_v2	46,002,222	794	51.80%
16	15_00286_DP_CS	51	90.9	677	CS_v2	35,855,898	677	52.98%
16	15_00287_DP_CS	49	92	835	CS_v2	35,687,184	835	56.65%
16	15_00412_DP_CS	49	91.2	723	CS_v2	36,265,030	723	53.27%
16	CS11_14_01357	51	87.2	793	CS_v1	10,456,420	793	50.62%
16	CS11_14_01364	47	90.1	812	CS_v1	11,454,182	812	54.77%
16	CS11_14_02243	49	93.1	564	CS_v1	5,687,884	564	65.87%
16	CS11_14_02316	49	90.4	1,071	CS_v1	9,843,236	1,071	60.47%
16	CS11_14_02333	49.5	90.7	74	CS_v1	8,700,284	74	30.64%
16	CS11_14_02487	54	88.8	75	CS_v1	9,176,280	75	34.87%
16	CS11_14_02500	51	88.2	1,130	CS_v1	12,059,828	1,130	59.59%
16	CS11_14_02688	50	90.4	882	CS_v2	52,885,534	882	14.90%
16	CS11_14_03372	50	89.5	1,335	CS_v2	51,628,328	1,335	15.72%
16	D_15_00804_DP_CS	50	89.1	1,010	CS_v2	42,808,372	1,010	54.56%
16	D_15_00857_DP_CS	50	88.5	902	CS_v2	41,771,306	902	55.85%
16	D_15_00858_DP_CS	50	89.1	721	CS_v2	38,087,448	721	55.06%
16	D_15_01017_DP_CS	49	90.8	728	CS_v2	40,758,894	728	54.79%
16	D_15_01161_DP_CS	49	91.3	954	CS_v2	39,096,336	954	57.34%
16	D_15_01163_DP_CS	50	90.3	966	CS_v2	39,886,686	966	56.24%
16	D_15_01164_DP_CS	48	90.9	966	CS_v2	40,793,594	966	55.66%
16	D_15_01174_DP_CS	47	90.3	950	CS_v2	43,175,150	950	56.28%
16	D_15_01234_DP_CS	49	89.6	763	CS_v2	42,563,730	763	57.09%
16	D_15_01272_DP_CS	49	89.5	965	CS_v2	42,355,308	965	56.04%
16	D_15_01420_DP_CS	49	88.5	678	CS_v2	41,328,410	678	49.80%
16	D_15_01422_DP_CS	53	83.9	349	CS_v2	34,791,190	349	40.97%
16	D_15_01424_DP_CS	49	91.1	269	CS_v2	36,273,210	269	42.78%
16	D_15_01425_DP_CS	49	87.4	821	CS_v2	42,744,570	821	54.08%
16	D_15_01429_DP_CS	48	88.6	820	CS_v2	42,740,546	820	53.79%
16	D_15_01430_DP_CS	51	87.6	525	CS_v2	39,568,708	525	49.78%
16	D_15_01444_DP_CS	50	88.4	891	CS_v2	40,403,792	891	56.15%
16	D_15_01445_DP_CS	49	90.3	899	CS_v2	39,074,456	899	55.28%
16	D_15_01446_DP_CS	49	89.3	967	CS_v2	39,371,538	967	56.72%
16	D_15_01757_DP_CS	49	89.5	1,043	CS_v2	39,653,146	1,043	60.46%
16	D_15_01797_DP_CS	49	89.5	979	CS_v2	40,476,764	979	59.60%
14/15/17	15_00054_DP_CS	49	91.9	1,681	CS_v1	15,694,724	1,681	66.59%
14/15/17	15_00057_DP_CS	50	91.6	1,743	CS_v1	15,803,116	1,743	65.90%

The Oncologist
The official journal of the Society for Translational Oncology

Supplemental Table for:
Clinical application of targeted deep sequencing in solid-cancer patients: Utility of targeted deep sequencing for biomarker-selected clinical trial
Seung Tae Kim et al.

14/15/17	15_00060_DP_CS	51	91.2	877	CS_v1	14,664,638	877	54.18%
14/15/17	15_00068_DT_CS	46	92.5	1,770	CS_v1	15,876,578	1,770	66.94%
14/15/17	15_00141_DP_CS	53	89.7	855	CS_v1	13,526,812	855	51.83%
14/15/17	15_00169_DT_CS	46	91.1	1,336	CS_v1	14,931,574	1,336	58.00%
14/15/17	15_00205_DP_CS	52	89.8	981	CS_v1	13,255,048	981	58.92%
14/15/17	15_00220_DP_CS	47	90.7	1,283	CS_v1	11,437,256	1,283	70.58%
14/15/17	15_00226_DP_CS	49	89.2	1,374	CS_v1	14,021,574	1,374	63.17%
14/15/17	15_00256_DT_CS	49	89.3	1,315	CS_v2	46,620,231	1,503	52.81%
14/15/17	15_00272_DP_CS	48	88.6	917	CS_v2	45,480,678	917	55.62%
14/15/17	15_00282_DP_CS	49	92.1	726	CS_v2	39,348,630	726	53.02%
14/15/17	15_00285_DP_CS	48	91.9	960	CS_v2	38,578,068	960	56.44%
14/15/17	15_00288_DP_CS	48	91.3	908	CS_v2	37,752,254	908	55.58%
14/15/17	15_00289_DP_CS	46	92.3	908	CS_v2	37,637,108	908	56.27%
14/15/17	15_00423_DP_CS	46	90.7	957	CS_v2	36,519,980	957	58.69%
14/15/17	15_00430_DP_CS	50	91.1	689	CS_v2	42,028,682	689	52.37%
14/15/17	CS11_14_01302	46	90.3	689	CS_v1	9,032,218	689	54.57%
14/15/17	CS11_14_01310	45	90.2	940	CS_v1	9,070,146	940	61.42%
14/15/17	CS11_14_01314	46	89.8	1,811	CS_v1	17,851,116	1,811	63.59%
14/15/17	CS11_14_01327	47	90	640	CS_v1	9,799,322	640	53.17%
14/15/17	CS11_14_01328	47	89.8	766	CS_v1	9,465,658	766	56.17%
14/15/17	CS11_14_01332	46	90	792	CS_v1	10,833,492	792	54.49%
14/15/17	CS11_14_01362	47	90.3	488	CS_v1	10,489,104	488	48.49%
14/15/17	CS11_14_02244	45	93.8	591	CS_v1	4,883,184	591	67.17%
14/15/17	CS11_14_02307	49	89.2	926	CS_v1	9,165,766	926	61.89%
14/15/17	CS11_14_02317	49	89.9	1,058	CS_v1	11,165,824	1,058	58.87%
14/15/17	CS11_14_02338	49	92	482	CS_v1	10,707,228	482	67.15%
14/15/17	CS11_14_02339	47	90.9	1,368	CS_v1	13,634,766	1,368	62.80%
14/15/17	CS11_14_02344	46	91.6	1,095	CS_v1	10,684,252	1,095	62.88%
14/15/17	CS11_14_02348	46	91.1	1,102	CS_v1	11,961,084	1,102	61.97%
14/15/17	CS11_14_02489	48	90.7	1,091	CS_v1	11,698,958	1,091	67.23%
14/15/17	CS11_14_02499	51	87.5	1,458	CS_v1	14,244,110	1,458	61.74%
14/15/17	CS11_14_02502	50	89.7	1,467	CS_v1	15,426,574	1,467	62.00%
14/15/17	CS11_14_02993	47	91.2	1,100	CS_v2	51,598,880	1,100	15.26%
14/15/17	CS11_14_02994	48	90.8	511	CS_v2	39,448,416	511	13.86%
14/15/17	CS11_14_03163	49	91.1	1,021	CS_v2	47,954,936	1,021	15.63%
14/15/17	CS11_14_03229	47	92.4	1,057	CS_v2	43,895,858	1,057	14.96%
14/15/17	CS11_14_03236	46	90.3	1,423	CS_v2	58,987,602	1,423	16.07%
14/15/17	CS11_14_03362	45	89.6	1,245	CS_v2	45,736,626	1,245	16.18%
14/15/17	CS11_14_03370	49	88.2	1,207	CS_v2	47,018,308	1,207	15.98%
14/15/17	D_15_00803_DP_CS	49	89.7	799	CS_v2	40,823,724	799	52.28%
14/15/17	D_15_00806_DP_CS	48	90.1	959	CS_v2	39,834,886	959	55.90%
14/15/17	D_15_00808_DP_CS	48	91.1	894	CS_v2	42,892,654	894	54.67%
14/15/17	D_15_00809_DP_CS	47	90.5	1,000	CS_v2	42,333,564	1,000	53.50%
14/15/17	D_15_00810_DP_CS	49	90.4	532	CS_v2	43,102,688	532	45.24%
14/15/17	D_15_00811_DP_CS	51	89.3	466	CS_v2	41,600,556	466	43.89%
14/15/17	D_15_00856_DP_CS	48	90.5	611	CS_v2	43,214,996	611	51.79%
14/15/17	D_15_00859_DP_CS	48	89.6	939	CS_v2	39,842,948	939	56.85%
14/15/17	D_15_00860_DP_CS	50	88.7	895	CS_v2	41,252,854	895	55.87%
14/15/17	D_15_00861_DP_CS	50	90.4	95	CS_v2	33,442,934	95	34.79%
14/15/17	D_15_00862_DP_CS	49	88.3	691	CS_v2	37,939,980	691	55.74%
14/15/17	D_15_00865_DP_CS	49	90.3	172	CS_v2	35,832,142	172	36.20%

The Oncologist
The official journal of the Society for Translational Oncology

Supplemental Table for:
Clinical application of targeted deep sequencing in solid-cancer patients: Utility of targeted deep sequencing for biomarker-selected clinical trial
Seung Tae Kim et al.

14/15/17	D_15_01011_DP_CS	48	90.3	743	CS_v2	46,620,900	743	52.46%
14/15/17	D_15_01012_DP_CS	47	91.3	586	CS_v2	42,661,750	586	49.24%
14/15/17	D_15_01016_DP_CS	48	89.1	558	CS_v2	43,123,020	558	55.24%
14/15/17	D_15_01018_DP_CS	47	91	423	CS_v2	39,306,874	423	49.89%
14/15/17	D_15_01167_DP_CS	50	91.1	801	CS_v2	42,417,916	801	56.10%
14/15/17	D_15_01220_DP_CS	49	90	902	CS_v2	41,614,992	902	54.16%
14/15/17	D_15_01223_DP_CS	49	89.5	891	CS_v2	41,554,386	891	57.71%
14/15/17	D_15_01226_DP_CS	50	89.3	898	CS_v2	47,081,664	898	55.46%
14/15/17	D_15_01426_DP_CS	47	89.1	745	CS_v2	42,146,908	745	52.61%
14/15/17	D_15_01462_DP_CS	48	91.3	565	CS_v2	37,827,326	565	53.99%
14/15/17	D_15_01463_DP_CS	48	92.4	266	CS_v2	35,397,474	266	46.56%
14/15/17	D_15_01754_DP_CS	49	88.8	990	CS_v2	41,345,214	990	55.25%
14/15/17	D_15_01793_DP_CS	50	90.1	782	CS_v2	40,286,530	782	56.74%
14/15/17	D_15_05058_DP_CS	52	90.2	1,023	CS_v2	41,671,428	1,023	55.70%